STOCK TITAN

enVVeno Medical Corporation - $NVNO STOCK NEWS

Welcome to our dedicated page for enVVeno Medical Corporation news (Ticker: $NVNO), a resource for investors and traders seeking the latest updates and insights on enVVeno Medical Corporation stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect enVVeno Medical Corporation's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of enVVeno Medical Corporation's position in the market.

Rhea-AI Summary
enVVeno Medical CEO to participate in Virtual Investor Ask the CEO Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary
enVVeno achieves full enrollment in SAVVE trial for VenoValve, expects topline data in Q4 2023 and FDA approval in Q3 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.72%
Tags
none
-
Rhea-AI Summary
enVVeno Medical Corporation plans to expedite the development of its enVVe transcatheter based replacement venous valve, shortening the development cycle by approximately 6 months. The company aims to begin preparations for the enVVe pivotal trial and expects to seek an Investigational Device Exemption (IDE) by the end of 2024. enVVe is designed to treat severe Chronic Venous Insufficiency (CVI) and offers a non-surgical, minimally invasive procedure. The Company is also developing the VenoValve, a replacement venous valve implanted via open surgical procedure.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.72%
Tags
none
Rhea-AI Summary
enVVeno Medical secures $28 million in funding from institutional investors
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.72%
Tags
none
-
Rhea-AI Summary
enVVeno Medical Corporation (NASDAQ:NVNO) reported financial results for Q2 2023, ending with $29.8M in cash and investments. The quarterly burn was $4.4M, aligning with guidance. The company expects to fund its operations through the release of topline safety and efficacy data from the SAVVE study and the end of 2024. Clinical highlights include progress in the SAVVE pivotal trial and plans for the enVVe valve. Financially, net losses decreased by 8% compared to Q2 2022, with a decrease in operating expenses and an increase in other income.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.28%
Tags
-
Rhea-AI Summary
NVNO: enVVeno Medical Corporation to Host Virtual KOL Event for VenoValve® Study
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.36%
Tags
conferences
Rhea-AI Summary
enVVeno Medical Corporation provided an update on enrollment for its SAVVE U.S. pivotal study for the VenoValve. To date, 57 patients have been enrolled in the study, and full enrollment is expected by the end of 2023. The company will be participating in an investor event on July 13 and a KOL event on July 18.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.56%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.85%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.18%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.81%
Tags
conferences
enVVeno Medical Corporation

Nasdaq:NVNO

NVNO Rankings

NVNO Stock Data

67.38M
12.56M
0.39%
35.04%
6.17%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States of America
IRVINE

About NVNO

hancock jaffe laboratories, inc. is a medical device company based out of 2807 mcgaw ave, irvine, ca, united states.